Liu et al. (2020), China  Retrospective cohort and case study/Zhongnan Hospital of Wuhan University Dawu County People's Hospital  124 patients, 22 patients:
12 therapy (mean age 53), 10 control (mean age 58)  CT, PCR  Serum  124 confirmed COVID‐19 cases, 12 HCOV infected patients  Blood: (Study 1) decreased platelet: 25 (20.2%), prolonged PT: 77 (62.1%), increased FIB: 27 (21.8%), and increased D‐dimer: 26 (21.0%)
Spectrum of disease: (study 2) severe cases: 6 mild cases: 4 critically ill: 2
CT: (study 2) Bilateral pneumonia: all  Study 1: hypercoagulability
Study 2: cough: all shortness of breath: most of them, nausea and vomiting: 60.0%/DM, cardiovascular and cerebrovascular diseases: 4 patients from the DIP, 5 patients control group  –  1  Therapy: Dipyridamole (150 mg in three separate doses for 7 consecutive days), antiviral (ribavirin, 0.5 g, Q12hr), corticoid (methylprednisolone sodium succinate, 40 mg, qd), oxygen therapy, nutritional support
Results and interpretation: significant increase in platelet/lymphocyte, significant decrease in D‐dimer levels
Discharged patients: 50% of severe cases and all 4 mild cases.
Dipyridamole adjunctive therapy could significantly reduce viral replication, inhibits hypercoagulability and improves immune recovery